Table of Contents Author Guidelines Submit a Manuscript
Gastroenterology Research and Practice
Volume 2017, Article ID 4139656, 9 pages
https://doi.org/10.1155/2017/4139656
Research Article

Serology of Viral Infections and Tuberculosis Screening in an IBD Population Referred to a Tertiary Centre of Southern Italy

1Department of Clinical and Experimental Medicine, Clinical Unit for Chronic Bowel Disorders, IBD-Unit, University of Messina, Messina, Italy
2Infectious Diseases, Department of Human Pathology, University Hospital of Messina, Messina, Italy
3Department of Economics, University of Messina, Messina, Italy

Correspondence should be addressed to Marco Ardesia; moc.liamg@aisedra.ocram

Received 2 May 2017; Revised 22 July 2017; Accepted 25 July 2017; Published 17 September 2017

Academic Editor: Cristiano Pagnini

Copyright © 2017 Marco Ardesia et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. C. Baumgart and W. J. Sandborn, “Crohn’s disease,” Lancet, vol. 380, no. 9853, pp. 1590–1605, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. I. Ordás, L. Eckmann, M. Talamini, D. C. Baumgart, and W. J. Sandborn, “Ulcerative colitis,” Lancet, vol. 380, no. 9853, pp. 1606–1619, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. F. Gomollón, A. Dignass, V. Annese et al., “3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: part 1: diagnosis and medical management,” Journal of Crohn's & Colitis, vol. 11, no. 1, pp. 3–25, 2017. View at Publisher · View at Google Scholar
  4. A. Dignass, J. O. Lindsay, A. Sturm et al., “Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management,” Journal of Crohn’s & Colitis, vol. 6, no. 10, pp. 991–1030, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. R. V. Bryant, W. J. Sandborn, and S. P. Travis, “Introducing vedolizumab to clinical practice: who, when, and how?” Journal of Crohn's & Colitis, vol. 9, no. 4, pp. 356–366, 2015. View at Publisher · View at Google Scholar · View at Scopus
  6. P. Gionchetti, F. Rizzello, V. Annese et al., “Use of corticosteroids and immunosuppressive drugs in inflammatory bowel disease: clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease,” Digestive and Liver Disease, vol. 49, no. 6, pp. 604–617, 2017. View at Publisher · View at Google Scholar
  7. D. D. Chaplin, “Overview of the immune response,” The Journal of Allergy and Clinical Immunology, vol. 125, Supplement 2, no. 2, pp. S3–S23, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Toruner, E. V. Jr Loftus, W. S. Harmsen et al., “Risk factors for opportunistic infections in patients with inflammatory bowel disease,” Gastroenterology, vol. 134, no. 4, pp. 929–936, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. W. Fries, M. Cottone, and A. Cascio, “Systematic review: macrophage activation syndrome in inflammatory bowel disease,” Alimentary Pharmacology & Therapeutics, vol. 37, no. 11, pp. 1033–1045, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Cascio, C. Iaria, P. Ruggeri, and W. Fries, “Cytomegalovirus pneumonia in patients with inflammatory bowel disease: a systematic review,” International Journal of Infectious Diseases, vol. 16, no. 7, pp. e474–e479, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. L. Beaugerie, N. Brousse, A. M. Bouvier et al., “Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study,” Lancet, vol. 374, no. 9701, pp. 1617–1625, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. M. J. Shale, C. H. Seow, C. S. Coffin, G. G. Kaplan, R. Panaccione, and S. Ghosh, “Review article: chronic viral infection in the anti-tumour necrosis factor therapy era in inflammatory bowel disease,” Alimentary Pharmacology & Therapeutics, vol. 31, no. 1, pp. 20–34, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. J. F. Rahier, F. Magro, C. Abreu et al., “Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease,” Journal of Crohn's & Colitis, vol. 8, no. 6, pp. 443–468, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. M. S. Silverberg, J. Satsangi, T. Ahmad et al., “Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology,” Canadian Journal of Gastroenterology, vol. 19, Supplement A, pp. 5A–36A, 2005. View at Google Scholar
  15. A. Belle, C. Baumann, M. A. Bigard et al., “Impact of immunosuppressive therapy on hepatitis B vaccination in inflammatory bowel diseases,” European Journal of Gastroenterology & Hepatology, vol. 27, no. 8, pp. 877–881, 2015. View at Publisher · View at Google Scholar · View at Scopus
  16. M. E. Altunöz, E. Senateş, A. Yeşil, T. Calhan, and A. O. Ovünç, “Patients with inflammatory bowel disease have a lower response rate to HBV vaccination compared to controls,” Digestive Diseases and Sciences, vol. 57, no. 4, pp. 1039–1044, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. E. Waszczuk, K. M. Waszczuk, A. Mulak, and L. Paradowski, “Inadequate seroprotection against hepatitis B virus and one detected case of hepatitis C virus infection among patients with inflammatory bowel disease,” European Journal of Gastroenterology & Hepatology, vol. 28, no. 6, pp. 628–632, 2016. View at Publisher · View at Google Scholar · View at Scopus
  18. A. R. Zanetti, A. Mariano, L. Romanò et al., “Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study,” Lancet, vol. 366, no. 9494, pp. 1379–1384, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. M. S. Linton, K. Kroeker, D. Fedorak, L. Dieleman, and R. N. Fedorak, “Prevalence of Epstein–Barr virus in a population of patients with inflammatory bowel disease: a prospective cohort study,” Alimentary Pharmacology & Therapeutics, vol. 38, no. 10, pp. 1248–1254, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. R. Di Stefano, T. Stroffolini, D. Ferraro et al., “Endemic hepatitis C virus infection in a Sicilian town: further evidence for iatrogenic transmission,” Journal of Medical Virology, vol. 67, no. 3, pp. 339–344, 2002. View at Google Scholar
  21. L. Biancone, M. Pavia, G. Del Vecchio Blanco et al., “Hepatitis B and C virus infection in Crohn’s disease,” Inflammatory Bowel Diseases, vol. 7, no. 4, pp. 287–294, 2001. View at Google Scholar
  22. A. Papa, C. Felice, M. Marzo et al., “Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor-α agents,” Journal of Crohn's & Colitis, vol. 7, no. 2, pp. 113–119, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. J. B. Chevaux, A. Nani, A. Oussalah et al., “Prevalence of hepatitis B and C and risk factors for nonvaccination in inflammatory bowel disease patients in Northeast France,” Inflammatory Bowel Diseases, vol. 16, no. 6, pp. 916–924, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. C. Loras, C. Saro, F. Gonzalez-Huix et al., “Prevalence and factors related to hepatitis B and C in inflammatory bowel disease patients in Spain: a nationwide, multicenter study,” The American Journal of Gastroenterology, vol. 104, no. 1, pp. 57–63, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. M. L. Huang, X. T. Xu, J. Shen, Y. Q. Qiao, Z. H. Dai, and Z. H. Ran, “Prevalence and factors related to hepatitis B and C infection in inflammatory bowel disease patients in China: a retrospective study,” Journal of Crohn's & Colitis, vol. 8, no. 4, pp. 282–287, 2014. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Ardesia, G. Costantino, and W. Fries, “Lower response to the hepatitis B vaccine in future inflammatory bowel disease patients,” European Journal of Gastroenterology & Hepatology, vol. 28, no. 9, pp. 1101-1102, 2016. View at Publisher · View at Google Scholar · View at Scopus
  27. C. Cekic, F. Aslan, A. Krc et al., “Evaluation of factors associated with response to hepatitis B vaccination in patients with inflammatory bowel disease,” Medicine, vol. 94, no. 22, article e940, 2015. View at Publisher · View at Google Scholar · View at Scopus
  28. J. P. Gisbert, J. R. Villagrasa, A. Rodríguez-Nogueiras, and M. Chaparro, “Efficacy of hepatitis B vaccination and revaccination and factors impacting on response in patients with inflammatory bowel disease,” The American Journal of Gastroenterology, vol. 107, no. 10, pp. 1460–1466, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. J. I. Cohen, “Epstein-Barr virus infection,” The New England Journal of Medicine, vol. 343, no. 7, pp. 481–492, 2000. View at Publisher · View at Google Scholar · View at Scopus
  30. S. Riestra, R. de Francisco, I. Perez et al., “Serology of viral infections in patients with inflammatory bowel disease,” Journal of Crohn's & Colitis, vol. 7, Supplement 1, p. S158, 2013. View at Publisher · View at Google Scholar
  31. R. de Francisco, S. Riestra, I. Pérez-Martínez et al., “Impact on clinical practice of Epstein-Barr virus infection in patients with inflammatory bowel disease,” Journal of Crohn's & Colitis, vol. 11, Supplement 1, pp. S32–S33, 2017. View at Publisher · View at Google Scholar
  32. J. S. Hyams, M. C. Dubinsky, R. N. Baldassano Colletti RB et al., “Infliximab is not associated with increased risk of malignancy or hemophagocytic lymphohistiocytosis in pediatric patients with inflammatory bowel disease,” Gastroenterology, vol. 152, pp. 1901–1914, 2017. View at Publisher · View at Google Scholar
  33. J. F. Rahier, S. Ben-Horin, Y. Chowers et al., “European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease,” Journal of Crohn's & Colitis, vol. 3, no. 2, article 21172250, pp. 47–91, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. T. Crough and R. Khanna, “Immunobiology of human cytomegalovirus: from bench to bedside,” Clinical Microbiology Reviews, vol. 22, no. 1, pp. 76–98, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. F. Yi, J. Zhao, R. V. Luckheeram et al., “The prevalence and risk factors of cytomegalovirus infection in inflammatory bowel disease in Wuhan, Central China,” Virology Journal, vol. 10, no. 43, 2013. View at Publisher · View at Google Scholar · View at Scopus
  36. X. W. Wu, L. Wu, H. Z. Ji, and F. Y. Wang, “Relationship between cytomegalovirus infection and steroid resistance in inflammatory bowel disease: a meta-analysis,” Digestive Diseases and Sciences, vol. 60, no. 11, pp. 3203–3208, 2015. View at Publisher · View at Google Scholar · View at Scopus
  37. K. Sager, S. Alam, A. Bond, L. Chinnappan, and C. S. Probert, “Review article: cytomegalovirus and inflammatory bowel disease,” Alimentary Pharmacology & Therapeutics, vol. 41, no. 8, pp. 725–733, 2015. View at Publisher · View at Google Scholar · View at Scopus
  38. G. Lawlor and A. C. Moss, “Cytomegalovirus in inflammatory bowel disease: pathogen or innocent bystander?” Inflammatory Bowel Diseases, vol. 16, no. 9, pp. 1620–1627, 2010. View at Publisher · View at Google Scholar · View at Scopus
  39. M. A. Presti, G. Costantino, A. Della Torre, A. Belvedere, A. Cascio, and W. Fries, “Severe CMV-related pneumonia complicated by the hemophagocytic lymphohistiocytic (HLH) syndrome in quiescent Crohn’s colitis: harmful cure?” Inflammatory Bowel Diseases, vol. 17, no. 11, pp. E145–E146, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. N. L. Baird, X. Yu, R. J. Cohrs, and D. Gilden, “Varicella zoster virus (VZV)-human neuron interaction,” Virus, vol. 5, no. 9, pp. 2106–2115, 2013. View at Publisher · View at Google Scholar · View at Scopus
  41. F. Ansari, R. D. Baker, R. Patel, and S. S. Baker, “Varicella immunity in inflammatory bowel disease,” Journal of Pediatric Gastroenterology and Nutrition, vol. 53, no. 4, pp. 386–388, 2011. View at Publisher · View at Google Scholar · View at Scopus
  42. G. Cullen, R. P. Baden, and A. S. Cheifetz, “Varicella zoster virus infection in inflammatory bowel disease,” Inflammatory Bowel Diseases, vol. 18, no. 12, pp. 2392–2403, 2012. View at Publisher · View at Google Scholar · View at Scopus
  43. G. Andrisani, A. Armuzzi, and A. Papa, “Comparison of Quantiferon-TB Gold versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease patients,” Journal of Gastrointestinal and Liver Diseases, vol. 22, no. 1, pp. 21–25, 2013. View at Google Scholar
  44. F. M. Marx, L. Fiebig, B. Hauer et al., “Higher rate of tuberculosis in second generation migrants compared to native residents in a metropolitan setting in Western Europe,” PLoS One, vol. 10, no. 6, article e0119693, 2015. View at Publisher · View at Google Scholar · View at Scopus
  45. C. Çekiç, F. Aslan, S. Vatansever et al., “Latent tuberculosis screening tests and active tuberculosis infection rates in Turkish inflammatory bowel disease patients under anti-tumor necrosis factor therapy,” Annals of Gastroenterology, vol. 28, no. 2, pp. 241–246, 2015. View at Google Scholar
  46. F. N. Aberra, N. Stettler, C. Brensinger, G. R. Lichtenstein, and J. D. Lewis, “Risk for active tuberculosis in inflammatory bowel disease patients,” Clinical Gastroenterology and Hepatology, vol. 5, no. 9, pp. 1070–1075, 2007. View at Publisher · View at Google Scholar · View at Scopus